vs

Side-by-side financial comparison of LandBridge Co LLC (LB) and MEDIFAST INC (MED). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $56.8M, roughly 1.3× LandBridge Co LLC). On growth, LandBridge Co LLC posted the faster year-over-year revenue change (55.6% vs -36.9%). LandBridge Co LLC produced more free cash flow last quarter ($122.0M vs $-6.6M). Over the past eight quarters, LandBridge Co LLC's revenue compounded faster (72.8% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

LB vs MED — Head-to-Head

Bigger by revenue
MED
MED
1.3× larger
MED
$75.1M
$56.8M
LB
Growing faster (revenue YoY)
LB
LB
+92.5% gap
LB
55.6%
-36.9%
MED
More free cash flow
LB
LB
$128.7M more FCF
LB
$122.0M
$-6.6M
MED
Faster 2-yr revenue CAGR
LB
LB
Annualised
LB
72.8%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LB
LB
MED
MED
Revenue
$56.8M
$75.1M
Net Profit
$8.1M
Gross Margin
69.4%
Operating Margin
60.0%
-10.4%
Net Margin
14.2%
Revenue YoY
55.6%
-36.9%
Net Profit YoY
-83.7%
EPS (diluted)
$0.24
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LB
LB
MED
MED
Q4 25
$56.8M
$75.1M
Q3 25
$50.8M
$89.4M
Q2 25
$47.5M
$105.6M
Q1 25
$44.0M
$115.7M
Q4 24
$36.5M
$119.0M
Q3 24
$28.5M
$140.2M
Q2 24
$26.0M
$168.6M
Q1 24
$19.0M
$174.7M
Net Profit
LB
LB
MED
MED
Q4 25
$8.1M
Q3 25
$8.1M
$-2.3M
Q2 25
$7.5M
$2.5M
Q1 25
$6.5M
$-772.0K
Q4 24
$49.3M
Q3 24
$2.7M
$1.1M
Q2 24
$-57.7M
$-8.2M
Q1 24
$10.8M
$8.3M
Gross Margin
LB
LB
MED
MED
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
LB
LB
MED
MED
Q4 25
60.0%
-10.4%
Q3 25
60.8%
-4.6%
Q2 25
60.0%
-1.0%
Q1 25
57.0%
-1.1%
Q4 24
49.4%
0.6%
Q3 24
11.2%
1.5%
Q2 24
-197.4%
-4.7%
Q1 24
71.1%
4.5%
Net Margin
LB
LB
MED
MED
Q4 25
14.2%
Q3 25
15.9%
-2.5%
Q2 25
15.8%
2.3%
Q1 25
14.7%
-0.7%
Q4 24
135.2%
Q3 24
9.3%
0.8%
Q2 24
-222.1%
-4.8%
Q1 24
56.7%
4.8%
EPS (diluted)
LB
LB
MED
MED
Q4 25
$0.24
$-1.64
Q3 25
$0.26
$-0.21
Q2 25
$0.24
$0.22
Q1 25
$0.20
$-0.07
Q4 24
$0.08
Q3 24
$-0.04
$0.10
Q2 24
$-0.75
Q1 24
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LB
LB
MED
MED
Cash + ST InvestmentsLiquidity on hand
$30.7M
$167.3M
Total DebtLower is stronger
$570.7M
Stockholders' EquityBook value
$340.3M
$198.9M
Total Assets
$1.4B
$248.0M
Debt / EquityLower = less leverage
1.68×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LB
LB
MED
MED
Q4 25
$30.7M
$167.3M
Q3 25
$28.3M
$173.5M
Q2 25
$20.3M
$162.7M
Q1 25
$14.9M
$164.6M
Q4 24
$37.0M
$162.3M
Q3 24
$14.4M
$170.0M
Q2 24
$24.6M
$163.5M
Q1 24
$156.4M
Total Debt
LB
LB
MED
MED
Q4 25
$570.7M
Q3 25
$366.1M
Q2 25
$370.9M
Q1 25
$375.5M
Q4 24
$385.5M
Q3 24
$242.4M
Q2 24
$360.8M
Q1 24
Stockholders' Equity
LB
LB
MED
MED
Q4 25
$340.3M
$198.9M
Q3 25
$272.0M
$214.7M
Q2 25
$266.4M
$216.0M
Q1 25
$217.0M
$211.0M
Q4 24
$211.8M
$210.1M
Q3 24
$97.2M
$207.3M
Q2 24
$296.4M
$205.3M
Q1 24
$162.3M
$211.0M
Total Assets
LB
LB
MED
MED
Q4 25
$1.4B
$248.0M
Q3 25
$1.1B
$268.2M
Q2 25
$1.1B
$269.3M
Q1 25
$1.0B
$280.0M
Q4 24
$1.0B
$284.2M
Q3 24
$689.9M
$291.2M
Q2 24
$710.5M
$293.5M
Q1 24
$302.8M
Debt / Equity
LB
LB
MED
MED
Q4 25
1.68×
Q3 25
1.35×
Q2 25
1.39×
Q1 25
1.73×
Q4 24
1.82×
Q3 24
2.49×
Q2 24
1.22×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LB
LB
MED
MED
Operating Cash FlowLast quarter
$126.3M
$-5.3M
Free Cash FlowOCF − Capex
$122.0M
$-6.6M
FCF MarginFCF / Revenue
214.9%
-8.8%
Capex IntensityCapex / Revenue
7.5%
1.8%
Cash ConversionOCF / Net Profit
15.68×
TTM Free Cash FlowTrailing 4 quarters
$207.7M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LB
LB
MED
MED
Q4 25
$126.3M
$-5.3M
Q3 25
$34.9M
$12.1M
Q2 25
$37.3M
$-3.4M
Q1 25
$15.9M
$3.4M
Q4 24
$67.6M
$-4.9M
Q3 24
$7.5M
$9.1M
Q2 24
$16.0M
$13.1M
Q1 24
$17.2M
$7.3M
Free Cash Flow
LB
LB
MED
MED
Q4 25
$122.0M
$-6.6M
Q3 25
$33.7M
$10.8M
Q2 25
$36.1M
$-4.8M
Q1 25
$15.8M
$1.9M
Q4 24
$66.7M
$-7.2M
Q3 24
$7.1M
$7.7M
Q2 24
$15.7M
$11.1M
Q1 24
$17.1M
$5.4M
FCF Margin
LB
LB
MED
MED
Q4 25
214.9%
-8.8%
Q3 25
66.3%
12.0%
Q2 25
75.9%
-4.5%
Q1 25
36.0%
1.6%
Q4 24
182.6%
-6.1%
Q3 24
25.1%
5.5%
Q2 24
60.4%
6.6%
Q1 24
90.1%
3.1%
Capex Intensity
LB
LB
MED
MED
Q4 25
7.5%
1.8%
Q3 25
2.3%
1.5%
Q2 25
2.6%
1.3%
Q1 25
0.2%
1.3%
Q4 24
2.7%
1.9%
Q3 24
1.1%
1.0%
Q2 24
1.4%
1.1%
Q1 24
0.5%
1.1%
Cash Conversion
LB
LB
MED
MED
Q4 25
15.68×
Q3 25
4.31×
Q2 25
4.98×
-1.36×
Q1 25
2.46×
Q4 24
1.37×
Q3 24
2.80×
8.04×
Q2 24
Q1 24
1.60×
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons